

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse IFN-alpha 2/IFNA2 in direct ELISA. In direct ELISAs, no cross-reactivity with mouse IFN-alpha 1, 4, 9, 11, 12 and 15 was observed.
Source	Monoclonal Rat IgG _{2A} Clone # 996586
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Human embryonic kidney cell, HEK293-derived mouse IFN-alpha 2/IFNA2 Cys24-Glu190 Accession # P01573
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

ELISA Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Interferon-alpha 2 (IFNα-2) is one of 14 subtypes within the IFN-α class of Type I Interferons (1). The members of the IFN-α class, also known as alpha leukocyte interferons, encompass a group of distinct but closely related proteins which share approximately 80% amino acid (aa) sequence identity and have a similar globular structure composed of five alpha-helices (1, 3, 4). IFN-α class members signal through a common cell surface receptor complex composed of IFN-αR2 and IFN-αR1 subunits (3). As the first highly active IFN to be cloned and produced, IFNα-2 has become the prototypic IFN for academic and pharmaceutical research (2). The mature extracellular domain (ECD) of mouse IFNα-2 shares 60% and 83% aa sequence identity with human and rat, respectively. Murine IFN-α2 can eliminate cardiac viral load and protect cardiomyocytes from injury in animals infected with coxsackievirus B3 (CVB3) (5). IFN α-2 derived mutants with reduced IFNAR2 binding inhibited HIV replication and mutants with more IFNAR1 binding potentiated antiviral activity (6).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.